CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a mixed sentiment. The financial guidance and new developments show promise, but lack specifics and clarity, especially in the Q&A section, where management avoided providing detailed responses. The absence of a market cap makes it difficult to assess the stock's potential movement accurately. However, the company's ongoing efforts in product development and strategic plans for various tumor types provide a balanced outlook, resulting in a neutral sentiment.
Key Financial Performance
Confirmed Overall Response Rate (ORR) at 10 mg/kg 32%, with a year-over-year improvement from earlier data. This improvement is attributed to dose optimization and better management of adverse events.
Confirmed Overall Response Rate (ORR) at 8.6 mg/kg 20%, with a year-over-year improvement. The improvement is due to dose optimization and enhanced prophylactic strategies.
Preliminary Progression-Free Survival (PFS) at 10 mg/kg 7.1 months, improved from 5.8 months in May 2025. The improvement is attributed to dose optimization and better adverse event management.
Preliminary Progression-Free Survival (PFS) at 8.6 mg/kg 6.8 months, showing improvement due to dose optimization and better adverse event management.
Grade 3 Diarrhea Rate in Dose Optimization Cohorts 10%, reduced from 29% in earlier cohorts. The reduction is due to mandatory dual prophylaxis with loperamide and budesonide.
Treatment Discontinuation Rate Due to Adverse Events 11%, consistent across cohorts, indicating a manageable safety profile.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Varseta-M Phase I Data: Positive Phase I dose expansion data for Varseta-M in late-line colorectal cancer patients. Demonstrated 32% confirmed overall response rate at 10 mg/kg and 20% at 8.6 mg/kg. Progression-free survival improved to 6.8-7.1 months. Safety profile improved with reduced grade 3 diarrhea to 10% in dose optimization cohorts.
Colorectal Cancer Market Opportunity: Colorectal cancer (CRC) is a large untapped market with 1.9 million annual diagnoses globally, expected to grow to 3 million by 2040. Late-line CRC market in the U.S. alone projected to have 45,000 addressable patients by 2040, representing a multibillion-dollar opportunity.
Dose Optimization: Implemented adjusted ideal body-weight dosing and mandatory dual prophylaxis strategies, leading to improved safety and tolerability of Varseta-M.
Future Development Plans: Plans to initiate registrational studies for Varseta-M in late-line CRC by 2027. Exploring earlier line CRC treatment and expansion into other EpCAM-positive tumors. Combination studies with bevacizumab and chemotherapy are also planned.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges that forward-looking statements are subject to inherent uncertainties and risks, many of which are outside of their control. This includes potential challenges in obtaining regulatory approvals for Varseta-M.
Safety Profile Challenges: The management of treatment-related adverse events, particularly grade 3 diarrhea, remains a challenge. Although progress has been made with prophylactic strategies, the safety profile of Varseta-M still requires optimization to ensure broader patient tolerability.
Dose Optimization Risks: The ongoing dose optimization process introduces uncertainties regarding the final dose selection for late-stage development and registration. Adjustments in dosing strategies may impact efficacy and safety outcomes.
Market Competition: While there is no approved ADC for CRC, the company faces potential competitive pressures from other emerging therapies targeting CRC and other EpCAM-positive tumors.
Strategic Execution Risks: The company’s ambitious plans to expand Varseta-M into earlier CRC lines, other EpCAM-positive tumors, and combination therapies with bevacizumab and chemotherapy require significant resources and precise execution. Delays or missteps could impact timelines and market opportunities.
Economic and Market Uncertainties: The projected multibillion-dollar market opportunity for Varseta-M in CRC is contingent on favorable market conditions and successful commercialization efforts, which are inherently uncertain.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future Registrational Studies: CytomX plans to initiate registrational studies for Varseta-M in the first half of 2027, focusing on late-line colorectal cancer (CRC).
Market Opportunity: The late-line CRC market is projected to have over 45,000 addressable patients in the U.S. by 2040, representing a multibillion-dollar opportunity. CytomX also aims to expand Varseta-M into earlier CRC treatment lines and other EpCAM-positive tumors.
Dose Optimization: Ongoing dose optimization efforts for Varseta-M aim to improve safety and tolerability, particularly by reducing severe diarrhea rates. Adjusted ideal body weight dosing and mandatory dual prophylaxis strategies are being implemented.
Combination Studies: CytomX has initiated Phase I studies of Varseta-M in combination with bevacizumab, with initial data expected late 2026 or early 2027. Additional combination studies with bevacizumab plus chemotherapy are planned to start by the end of 2026.
Expansion Beyond CRC: CytomX plans to start its first clinical study of Varseta-M outside of CRC by the end of 2026, targeting other EpCAM-positive tumors.
Progression-Free Survival (PFS): Preliminary PFS for Varseta-M has improved to 6.8-7.1 months at higher doses, with potential for further improvement as data matures.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How large is the anticipated pivotal trial for Varseta and what are the potential next indications beyond CRC?
A:The size of the pivotal trial is still under consideration, but it is expected to be manageable and executed quickly. The company is excited about the potential of EpCAM in other tumors such as gastric, pancreatic, lung, ovarian, and certain breast cancers, with plans to move into other tumor types by the end of the year.
Q:How should the implementation of the diarrhea prophylactic protocol be considered for real-world use?
A:The prophylactic protocol, including loperamide and budesonide, is expected to be adhered to in real-world use. Budesonide has shown effectiveness and high patient compliance, and the protocol will be refined and optimized further.
Q:Will progression-free survival (PFS) be the sole primary endpoint for the pivotal trial?
A:No, the company is planning for overall survival (OS) to be the primary endpoint, as there is no precedent for PFS as the sole primary endpoint in late-line CRC. However, they are exploring all options to accelerate development.
Q:How does Varseta compare to other ADCs in development for CRC?
A:Varseta is a first-in-class anti-EpCAM ADC and may be best-in-class for CRC based on its competitive data set and safety profile. It has potential for earlier lines of treatment due to its combinability with frontline treatments.
Q:Have you analyzed the data for third-line-only patients, and what is the duration of diarrhea observed?
A:The company has not dissected the data for third-line-only patients but is optimistic about the drug's activity in earlier lines. The median time to onset of grade 3 diarrhea is about 5 weeks, and the updated prophylaxis strategy has reduced its incidence.
Q:What is the plan for dose optimization and adjusted ideal body weight dosing?
A:The adjusted ideal body weight dosing aims to decrease outliers and compress the dose range for consistent dosing. This should improve safety management and maximize clinical benefit.
Q:What are the confirmed partial responses in the 8.6 and 10 mg/kg cohorts, and what is the pivotal trial comparator arm?
A:The drug shows activity across heavily pretreated patients, but specific breakout data for the 8.6 and 10 mg/kg cohorts were not provided. The pivotal trial comparator arm is likely to be bevacizumab plus Lonsurf, the current standard of care in the third-line setting.
Q:What is the plan for implementing prophylaxis in combination approaches and earlier treatment lines?
A:The dual use of loperamide and budesonide is considered effective and convenient for patients. The company does not foresee significant challenges in implementing this prophylaxis in earlier treatment lines.
Q:What is the dose selection strategy for bevacizumab combination studies and other tumor types?
A:Dose selection for bevacizumab combination studies and other tumor types is a work in progress. The company has narrowed the active doses to 8.6 and 10 mg/kg and is learning more to finalize the go-forward dose for the first pivotal trial.
Q:Will KRAS wild-type and mutant patients be considered in earlier line settings?
A:Yes, Varseta has shown activity in both KRAS wild-type and mutant patients, and the drug is being developed for all-comer CRC without patient selection.
Q:Are there plans to reevaluate higher dose cohorts (11 or 12 mg/kg) given the reduction in GI adverse events?
A:No, the company is satisfied with the current doses of 8.6 and 10 mg/kg and does not see a need to push the dose higher at this time.
Q:What are the focused indications for broadening studies for EpCAM-positive tumor types?
A:The company is exploring multiple opportunities in EpCAM-positive tumors, including gastric, pancreatic, lung, ovarian, and certain breast cancers. Specific study sizes and details will be provided later.
Q:What is the frequency and recurrence of grade 3 diarrhea events at the 8.6 and 10 mg/kg dose levels?
A:The focus is on preventing grade 3 diarrhea events with the optimized prophylaxis strategy. The company has not provided specific data on the recurrence of grade 3 diarrhea events.
Q:How much of the grade 3 diarrhea improvement is attributed to adjusted body weight dosing versus updated prophylaxis?
A:It is difficult to determine the exact contribution of adjusted body weight dosing versus updated prophylaxis, but both are believed to play significant roles in reducing grade 3 diarrhea.
Q:What is the median time on therapy for patients in the optimized safety cohort?
A:The median time on therapy for the optimized safety cohort is approximately 2 months, which aligns with the median time to onset of grade 3 diarrhea (5 weeks).
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the size of the pivotal trial, the exact breakout data for the 8.6 and 10 mg/kg cohorts, and the recurrence of grade 3 diarrhea events. They also did not disclose the specific study sizes for broadening studies in EpCAM-positive tumor types or the exact contribution of adjusted body weight dosing versus updated prophylaxis to the reduction in grade 3 diarrhea.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CRC
CytomX
Phase
baseline
body weight
cancer
cohort treatment
diarrhea grade
disease
dose level
dose optimization
drug
efficacy
enrollment
escalation expansion
expansion cohort
expansion dose
exposure
grade diarrhea
incidence grade
kg dose
mg kg
month treatment
observation
optimization cohort
patient escalation
patient optimization
prophylaxis
safety profile
slide
study
toxicity
treatment event
tumor
CTMX Transcript
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
Unknown3-16
The earnings call summary indicates a mixed sentiment. The financial guidance and new developments show promise, but lack specifics and clarity, especially in the Q&A section, where management avoided providing detailed responses. The absence of a market cap makes it difficult to assess the stock's potential movement accurately. However, the company's ongoing efforts in product development and strategic plans for various tumor types provide a balanced outlook, resulting in a neutral sentiment.
CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call reveals a significant decline in total revenue, primarily due to the completion of obligations in a major collaboration. While operating expenses decreased, the revenue drop is concerning. The Q&A section highlights some optimism about CX-2051's potential, but uncertainties remain, particularly regarding regulatory strategies and data updates. No guidance was provided, and management's evasiveness on certain questions adds to the negative sentiment. Overall, the financial performance and lack of clear guidance suggest a negative outlook for the stock price in the short term.
Carrier Global Corporation (CARR) Presents At Morgan Stanley's 13th Annual Laguna Conference Transcript
Neutral9-10
CTMX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
